Aaron P Rapoport
Affiliation: University of Maryland
- Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genesA P Rapoport
University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
Blood Cells Mol Dis 27:610-24. 2001..Flavopiridol was also cytotoxic to seven other BL cell lines tested. These data suggest that flavopiridol may have therapeutic value in the treatment of Burkitt's lymphoma...
- Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cellsAaron P Rapoport
University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, USA
Clin Cancer Res 15:4499-507. 2009..Here, we investigated the safety and kinetics of T-cell recovery after infusing ex-T at day +2 after transplant...
- Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cellsA P Rapoport
Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
Bone Marrow Transplant 33:53-60. 2004..Autotransplantation followed by costimulated autologous T cells is feasible for patients with chronic phase CML, who lack allogeneic donors and can be associated with molecular remissions...
- Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphomaA P Rapoport
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
Bone Marrow Transplant 34:883-90. 2004..5 years, EFS=87%). There were no treatment-related deaths during or after the CC phase. Post-transplant CC is feasible and well tolerated. The impact of this approach on EFS should be evaluated in a larger, randomized study...
- Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) comeA P Rapoport
University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
Bone Marrow Transplant 37:239-47. 2006....
- Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transferAaron P Rapoport
University of Maryland Greenebaum Cancer Center and Center for Vaccine Development, 22 South Greene Street Baltimore, Maryland 21201, USA
Nat Med 11:1230-7. 2005..05). In the setting of lymphopenia, combined vaccine therapy and adoptive T-cell transfer fosters the development of enhanced memory T-cell responses...
- Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myelomaAshraf Badros
University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
Clin Lymphoma Myeloma 7:210-6. 2006..In preclinical studies, bortezomib was shown to suppress tumor growth, sensitize malignant cells to apoptosis, and reverse chemotherapy resistance...
- Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literatureAshraf Badros
Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
Cancer 110:1042-9. 2007..Bortezomib is active in heavily pretreated multiple myeloma patients; the dose-limiting toxicity is peripheral neuropathy (PN)...
- Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patientsAshraf Z Badros
Greenebaum Cancer Center, Department of Pathology, University of Maryland, 22 S Greene St, Baltimore, MD 21201, USA
J Clin Oncol 23:4089-99. 2005..Bcl-2 regulates the mitochondrial apoptosis pathway that promotes chemotherapy resistance. Bcl-2 antisense oligonucleotide, G3139, targets Bcl-2 mRNA...
- Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myelomaAaron P Rapoport
University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA
Blood 117:788-97. 2011..This study was registered at www.clinicaltrials.gov as NCT00499577...
- Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignanciesBhavana Bhatnagar
Blood and Marrow Transplantation Program, the Marlene and Stewart Greenebaum Cancer Center, Department of Medicine, University of Maryland, Baltimore, MD, 21201, USA
Ann Hematol 93:653-60. 2014..Further studies with TBI-MEL in standard risk transplant patients are warranted...
- Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapyMerry Y Zhao
Department of Pathology, University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
Clin Cancer Res 15:1708-20. 2009..This study aimed to identify and evaluate molecular targets for the development of a novel combination chemotherapy to treat refractory and recurrent diffuse large B-cell lymphoma (DLBCL)...
- Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin diseaseDavid L Brauer
University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
Transfusion 52:2432-5. 2012..The drug has been widely used for treatment of multiple myeloma and myelodysplastic syndrome (MDS) associated with 5q-abnormality. The most common side effects are cytopenias, infections, and deep venous thrombosis...
- Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53Asit K Nandi
Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Biochem Biophys Res Commun 358:181-8. 2007..Together, our studies provide a plausible explanation for the role of PBK augmenting tumor cell growth following transient appearance in different types of progenitor cells in vivo as reported...
- c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomasFang Hu
Marlene and Stewart Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Leuk Res 37:447-54. 2013..In conclusion, a c-Myc-E2F1-PBK signaling pathway operates in high-grade lymphomas and may provide a useful target for novel antineoplastic therapeutics...
- Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposideJavier Bolaños-Meade
University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Room S9D07, Baltimore, MD 21201, USA
Leuk Res 27:313-21. 2003..However, patients of age equal to 60 years and those with poor-risk disease features still have poor CR and DFS, despite the addition of ATRA...
- Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patientsNaoko Takebe
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
Clin Cancer Res 10:8301-8. 2004..On the basis of our preclinical studies, we designed a clinical study to test our hypothesis that MMF has antimyeloma activity...
- Catastrophic antiphospholipid syndrome: atypical presentation in the setting of chronic graft versus host disease: case report and review of the literatureKarl M Kasamon
Department of Hematology, Greenebaum Cancer Center, University of Maryland, Baltimore 21201, USA
Haematologica 90:ECR17. 2005..The case is discussed in the framework of the existing literature and derives clinical practice recommendations for this rare but clinically devastating entity...
- Expression of PDZ-binding kinase (PBK) is regulated by cell cycle-specific transcription factors E2F and CREB/ATFAsit K Nandi
University of Maryland School of Medicine, Greenebaum Cancer Center, 655 W Baltimore Street, Baltimore, MD 21201, USA
Leuk Res 30:437-47. 2006..These findings may provide insight into the mechanisms that upregulate PBK expression in proliferative hematologic malignancies and down regulate its expression following growth arrest of leukemic cells...
- Detection of CD4(+) T-cell antibodies in a patient with idiopathic CD4 T lymphocytopenia and cryptococcal meningitisRachel B Salit
Department of Internal Medicine, The University of Maryland Medical Center, Baltimore, MD 21201, USA
Br J Haematol 139:133-7. 2007..61%) than the CD4(+) T cells of normal donors (3.94 +/- 1.77%). The reasons behind the development of these autoantibodies are explored...
- Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution studyFrancis K Buadi
Department of Medicine Division of Hematology Oncology Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
Am J Hematol 82:208-14. 2007..This study confirms the ability to treat a significant proportion of PTLD patients with chemotherapy or surgical resection (depending on presentation), without sacrificing graft function in those receiving chemotherapy...
- Large cell lymphoma presenting as a flare of colitis in a patient with common variable immune deficiencyMegan Dunnigan
Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA
Dig Dis Sci 52:830-4. 2007
- Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine AClarence Sarkodee-Adoo
Division of Hematology and Oncology, University of Maryland School of Medicine, Baltimore, USA
Transfusion 43:78-84. 2003..The optimal treatment of BMT-associated TMA is also not known...
- Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin lymphomaSaranya Chumsri
Leuk Lymphoma 48:616-8. 2007
- Immune responses to T-cell expansion + PCV immunizationAaron Rapoport; Fiscal Year: 2005..abstract_text> ..
- Immunotherapy after ASCT for MM Using hTERT Vaccination + Vaccine-primed T cellsAaron Rapoport; Fiscal Year: 2007..AIM 2: To assay for development of cellular immune responses to the hTERT multi-peptide vaccine in the cohort of HLA A2+ patients who receive the combination of the multi-peptide vaccine and the vaccine-primed and costimulated T-cells. ..